Announcements Trials

Browse Landscape

Phase

Status

Completed 5 Terminated 4 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Paclitaxel 5 Gemcitabine 3 Nivolumab 2 Injections 2 E 7107 2 Docetaxel 2 Carboplatin 2 Antibodies, Monoclonal 2 130-nm albumin-bound paclitaxel 2 venetoclax 1 trastuzumab biosimilar HLX02 1 taxane 1 spartalizumab 1 resiniferatoxin 1 poly(I).poly(c12,U) 1 pegamotecan 1 palbociclib 1 lenvatinib 1 imisopasem manganese 1 icotinib 1 gusacitinib 1 famitinib 1 eniluracil 1 dabrafenib 1 cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1 cobimetinib 1 brincidofovir 1 ammonium trichloro(dioxoethylene-O,O'-)tellurate 1 aldesleukin 1 abivertinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × INDUSTRY × HM781-36B × Clear all

NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡